Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Author(s): Benedetto Caroleo, Lidia Colangelo, Maria Donato, Marco Balestrieri, Mauro Soda, Caterina Palleria, Gianluca Sambataro, Sonia Cosentino, Lucia Muraca, Teresa Alcaro, Vincenzo Scorcia, Giovambattista De Sarro and Luca Gallelli*

DOI: 10.2174/2772432816666210903150454

DownloadDownload PDF Flyer Cite As
Direct-acting Antivirals Inducing HCV-RNA Sustained Suppression Improve Xerophthalmia in HCV-infected Patients

Page: [156 - 160] Pages: 5

  • * (Excluding Mailing and Handling)

Abstract

Background: Hepatitis C Virus (HCV) infection represents a global problem, and it is related to both hepatic and extra-hepatic manifestations (e.g., xerophthalmia). New direct-acting antivirals (DAAs), IFN-free treatments, are commonly used to manage HCV infection. However, the impact of new DAAs on dry eyes (xerophthalmia) is lacking. In this study, we evaluated its incidence in HCV patients and the effect of DAAs on this manifestation.

Methods: We performed an observational open-label non-randomized study in HCV patients from 01 April 2018 to 01 June 2020.

Results: Patients who satisfied the inclusion criteria underwent clinical and laboratory evaluation, Schirmer's test, and Break-up time test. Enrolled patients were divided in two groups: Group 1: HCV patients with xerophthalmia: 24 patients (16 male and 8 female), HCV-RNA 2,685,813 ± 1,145,698; Group 2: HCV patients without xerophthalmia: 35 patients (19 male and 16 female), HCV-RNA 2,614,757 ± 2,820,433. The follow-ups (3 and 6 months after the enrollment) documented an improvement in both eyes’ manifestations and HCV-infection (HCV-RNA undetected).

Conclusion: In conclusion, in this study, we reported that xerophthalmia could appear in HCV patients, and DAAs treatment reduces this manifestation without the development of adverse drug reactions.

Keywords: HCV-infection, dry-eye, direct antiviral agents, schirmer's test, DAAs treatment, xerophthalmia.

Graphical Abstract

[1]
Negro F. Epidemiology of hepatitis C in Europe. Dig Liver Dis 2014; 46(Suppl. 5): S158-64.
[http://dx.doi.org/10.1016/j.dld.2014.09.023] [PMID: 25453870]
[2]
Cacoub P, Gragnani L, Comarmond C, Zignego AL. Extrahepatic manifestations of chronic hepatitis C virus infection. Dig Liver Dis 2014; 46(Suppl. 5): S165-73.
[http://dx.doi.org/10.1016/j.dld.2014.10.005] [PMID: 25458776]
[3]
Ferri C, Sebastiani M, Giuggioli D, et al. Hepatitis C virus syndrome: A constellation of organ- and non-organ specific autoimmune disorders, B-cell non-Hodgkin’s lymphoma, and cancer. World J Hepatol 2015; 7(3): 327-43.
[http://dx.doi.org/10.4254/wjh.v7.i3.327] [PMID: 25848462]
[4]
Sambataro D, Sambataro G, Pignataro F, et al. Patients with interstitial lung disease secondary to autoimmune diseases: How to recognize them? Diagnostics (Basel) 2020; 10(4): E208.
[http://dx.doi.org/10.3390/diagnostics10040208] [PMID: 32283744]
[5]
Cornec D, Saraux A, Jousse-Joulin S, et al. The differential diagnosis of dry eyes, dry mouth, and parotidomegaly: A comprehensive review. Clin Rev Allergy Immunol 2015; 49(3): 278-87.
[http://dx.doi.org/10.1007/s12016-014-8431-1] [PMID: 24952023]
[6]
Bekibele C, Baiyeroju A, Ajaiyeoba A, Akang E, Ajayi B. Tear function and abnormalities of ocular surface: Relationship with subjective symptoms of dry eye in Ibadan, Nigeria. Middle East Afr J Ophthalmol 2008; 15(1): 12-5.
[http://dx.doi.org/10.4103/0974-9233.53369] [PMID: 20379423]
[7]
Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: A meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 2016; 150(7): 1599-608.
[http://dx.doi.org/10.1053/j.gastro.2016.02.039] [PMID: 26924097]
[8]
Zegans ME, Anninger W, Chapman C, Gordon SR. Ocular manifestations of hepatitis C virus infection. Curr Opin Ophthalmol 2002; 13(6): 423-7.
[http://dx.doi.org/10.1097/00055735-200212000-00014] [PMID: 12441848]
[9]
Fox RI, Stern M, Michelson P. Update in sjögren syndrome. Curr Opin Rheumatol 2000; 12(5): 391-8.
[http://dx.doi.org/10.1097/00002281-200009000-00007] [PMID: 10990175]
[10]
Cacoub P, Comarmond C, Desbois AC, Saadoun D. Rheumatologic manifestations of hepatitis C virus infection. Clin Liver Dis 2017; 21(3): 455-64.
[http://dx.doi.org/10.1016/j.cld.2017.03.002] [PMID: 28689585]
[11]
Macken L, Gelson W, Priest M, et al. Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort. J Med Virol 2019; 91(11): 1979-88.
[http://dx.doi.org/10.1002/jmv.25552] [PMID: 31329295]
[12]
McPhail J, Sims OT, Guo Y, Wooten D, Herndon JS, Massoud OI. Fibrosis improvement in patients with HCV treated with direct-acting antivirals. Eur J Gastroenterol Hepatol 2021; 33(7): 996-1000.
[http://dx.doi.org/10.1097/MEG.0000000000001821] [PMID: 32639414]
[13]
Chin Loy K, Galaydh F, Shaikh S. Correction: Retinopathy and uveitis associated with sofosbuvir therapy for chronic hepatitis C infection. Cureus 2016; 8(7): c3.
[PMID: 27610281]